TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38072236

Group type: EXPERIMENTAL
Intervention: Neonatal sleep intervention (SNOO responsive bassinet) plus usual care
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 110
Study: 38072307

Group type: EXPERIMENTAL
Intervention: Female patients undergoing PCI for AMI complicated by CS
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: After propensity score matching for female patients undergoing PCI for AMI complicated by CS
Number of subjects: 695
Study: 38072326

Group type: EXPERIMENTAL
Intervention: Nimorazole + IMRT
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo + IMRT
Number of subjects: 338
Study: 38072392

Group type: EXPERIMENTAL
Intervention: Situs Ambiguus (SA)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Situs Solitus (SS) or Situs Inversus Totalis (SIT)
Number of subjects: 397
Study: 38072471

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (VO2 max)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Muscular strength (handgrip)
Number of subjects: 317
Study: 38072483

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 1437

Group type: COMPARATOR
Intervention: Propofol (usual care)
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: Post-ICU outcomes
Number of subjects: 1437
Study: 38072485

Group type: EXPERIMENTAL
Intervention: Standard handout of nearby dental and aSDoH resources
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Geographically matched listing of aSDoH resources and a search link for identification of geographically matched dental resources
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Geographically matched resources along with personalised care navigation
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Enhanced standard care (control group)
Number of subjects: 2049
Study: 38072492

Group type: EXPERIMENTAL
Intervention: Angiography-derived FFR-guided PCI
Number of subjects: 1872

Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 1872
Study: 38072494

Group type: EXPERIMENTAL
Intervention: Live births (92%, n=3478)
Number of subjects: 3731

Group type: EXPERIMENTAL
Intervention: Miscarriages/abortions (5.5%, n=205)
Number of subjects: 3731

Group type: EXPERIMENTAL
Intervention: Stillbirths (2.6%, n=98)
Number of subjects: 3731

Group type: EXPERIMENTAL
Intervention: Home deliveries (22%, n=786)
Number of subjects: 3731

Group type: EXPERIMENTAL
Intervention: Low birth weight (<2500 g)
Number of subjects: 3731

Group type: EXPERIMENTAL
Intervention: Preterm births (gestational age <37 weeks)
Number of subjects: 3731

Group type: EXPERIMENTAL
Intervention: Maternal mortality rate
Number of subjects: 3731

Group type: EXPERIMENTAL
Intervention: Neonatal mortality rate
Number of subjects: 3731

Group type: EXPERIMENTAL
Intervention: Stillbirth rate
Number of subjects: 3731

Group type: EXPERIMENTAL
Intervention: Causes of neonatal deaths
Number of subjects: 3731
Study: 38072513

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 5 mg/day plus abemaciclib 150 mg b.i.d until disease progression/toxicity
Number of subjects: 29
Study: 38072514

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 5 mg daily
Number of subjects: 103

Group type: COMPARATOR
Intervention: Fulvestrant 500 mg (days 1, 15, and 29, then every 4 weeks)
Number of subjects: 103
Study: 38072625

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel) at a target dose level of 50 × 10
Number of subjects: 88
Study: 38072743

Group type: EXPERIMENTAL
Intervention: Pomalidomide, Bortezomib, and Dexamethasone (PVd)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Bortezomib and Dexamethasone (Vd)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Pomalidomide, Bortezomib, and Dexamethasone (PVd) with bortezomib dose adjustment
Number of subjects: 559
Study: 38072960

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab plus polatuzumab vedotin
Number of subjects: 120
Study: 38073038

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 38073039

Group type: EXPERIMENTAL
Intervention: uEV-MMP-7 in patients with rapid disease progression
Number of subjects: 59

Group type: COMPARATOR
Intervention: Whole urine MMP-7
Number of subjects: 59

Group type: COMPARATOR
Intervention: ADPKD tissue MMP-7 expression
Number of subjects: 59
Study: 38073180

Group type: EXPERIMENTAL
Intervention: Birth ball application
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Squatting position
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study: 38073386

Group type: EXPERIMENTAL
Intervention: Combined visual and auditory gamma-sensory stimulation (40 Hz for six months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 38
Study: 38073465

Group type: EXPERIMENTAL
Intervention: Online cognitive behavioral intervention with phone coaching
Number of subjects: 102

Group type: COMPARATOR
Intervention: Phone monitoring alone
Number of subjects: 102
Study: 38073563

Group type: EXPERIMENTAL
Intervention: Hypertensive individuals (systolic BP ≥130 mm Hg, diastolic BP ≥80 mm Hg, or use of antihypertensive medications) at 1 year postpartum
Number of subjects: 129

Group type: COMPARATOR
Intervention: Individuals with normalization of BP at 1 year postpartum
Number of subjects: 129
Study: 38073622

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (EVOO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (olive oil, OO)
Number of subjects: 0
Study: 38074133

Group type: EXPERIMENTAL
Intervention: Berberine Phytosome
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38074142

Group type: EXPERIMENTAL
Intervention: Ciprofol emulsion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal renal function)
Number of subjects: 0
Study: 38074293

Group type: EXPERIMENTAL
Intervention: VeriStrat® test (VS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MALDI-TOF analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DeepMALDI® analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LC-MS/MS
Number of subjects: 0
Study: 38074312

Group type: EXPERIMENTAL
Intervention: Sotrovimab treatment
Number of subjects: 0
Study: 38074489

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for obesity management, combined with sessions with a dietitian and a kinesiologist, for 16 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving sessions with a dietitian and a kinesiologist, without cognitive behavioral therapy, for 16 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for obesity management.
Number of subjects: 0
Study: 38074707

Group type: EXPERIMENTAL
Intervention: PET program (intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CREAtive writing Training (CREAT) program (active control)
Number of subjects: 0
Study: 38074719

Group type: EXPERIMENTAL
Intervention: 10 mg THC mixed with tobacco
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 mg THC mixed with tobacco
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 38075210

Group type: EXPERIMENTAL
Intervention: High protein low glycemic index diet
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 279
Study: 38075956

Group type: EXPERIMENTAL
Intervention: Home-based Exercise Therapy (HBET) program with behavior change intervention and smartphone app
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: WalkingPad app
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study: 38076348

Group type: EXPERIMENTAL
Intervention: Group I (eGFR <30 ml/min/1.73 m²)
Number of subjects: 2663

Group type: EXPERIMENTAL
Intervention: Group II (eGFR ≥30 and <60 ml/min/1.73 m²)
Number of subjects: 2663

Group type: EXPERIMENTAL
Intervention: Group III (eGFR ≥60 ml/min/1.73 m²)
Number of subjects: 2663
Study: 38076411

Group type: EXPERIMENTAL
Intervention: Recent HIV infection identified using the Maxim HIV-1 LAg-Avidity EIA assay as part of a recent infection testing algorithm (RITA)
Number of subjects: 6899

Group type: EXPERIMENTAL
Intervention: Annualized HIV incidence rate
Number of subjects: 6899

Group type: EXPERIMENTAL
Intervention: Age group comparison for recent HIV infection
Number of subjects: 6899
Study: 38076597

Group type: EXPERIMENTAL
Intervention: Combined cardiac PET/MRI
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard-of-Care Imaging (separate cardiac MRI, PET/CT, and SPECT perfusion imaging)
Number of subjects: 40
Study: 38076682

Group type: EXPERIMENTAL
Intervention: ADHD group (medicated daily for ADHD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-ADHD group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups after ten soccer headers
Number of subjects: 60
Study: 38077080

Group type: EXPERIMENTAL
Intervention: SMART-U intervention (12-week intensive educational sessions and 12-week remotely accessed telephone follow-up)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (eTAU)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: SMART-U intervention
Number of subjects: 188
Study: 38077106

Group type: EXPERIMENTAL
Intervention: level D-PPE
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: level C-PPE
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PAPR
Number of subjects: 30
Study: 38077184

Group type: EXPERIMENTAL
Intervention: Group yoga
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group low-impact exercise
Number of subjects: 0
Study: 38077399

Group type: EXPERIMENTAL
Intervention: Blood IFN-α2 level
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Neutralizing anti-IFN-α2 auto-antibodies
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Rapid decline of blood IFN-α2
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: High level of plasma SARS-CoV-2 RNA
Number of subjects: 140
Study: 38077624

Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted trivalent influenza vaccine (aTIV)
Number of subjects: 1779

Group type: COMPARATOR
Intervention: Quadrivalent inactivated influenza vaccine (QIV)
Number of subjects: 1779
Study: 38078711

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation
Number of subjects: 1878

Group type: EXPERIMENTAL
Intervention: Caprini risk score (CRS)
Number of subjects: 1878

Group type: EXPERIMENTAL
Intervention: Treatment of tributaries
Number of subjects: 1878

Group type: EXPERIMENTAL
Intervention: Treatment of perforating veins
Number of subjects: 1878
Study: 38078710

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) with micronet-covered plaque-sequestrating stents
Number of subjects: 60

Group type: COMPARATOR
Intervention: NPP-management (not per-protocol management)
Number of subjects: 60
Study: 38078866

Group type: EXPERIMENTAL
Intervention: Elranatamab
Number of subjects: 0
Study: 38078870

Group type: EXPERIMENTAL
Intervention: Tirzepatide (10 or 15 mg, once-weekly subcutaneous)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 670
Study: 38078898

Group type: EXPERIMENTAL
Intervention: Camonsertib monotherapy
Number of subjects: 60
Study: 38079084

Group type: EXPERIMENTAL
Intervention: PG-HPG nanoemulsion lubricant eye drops, self-administered one drop four times daily for 28 ± 2 days
Number of subjects: 119
Study: 38079089

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once daily orally until disease progression or unacceptable toxicity
Number of subjects: 17
Study: 38079095

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg oral daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Probe drug alone
Number of subjects: 32
Study: 38079201

Group type: EXPERIMENTAL
Intervention: ChatV health bot
Number of subjects: 40
Study: 38079324

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity during sport and leisure time (MVPA-SL) measured at diagnosis (T0) and 6, 12, 24, and 60 months (T6 to T60) postdiagnosis using the SQUASH questionnaire.
Number of subjects: 4900

Group type: COMPARATOR
Intervention: Comparison with an age- and sex-matched sample of the general Dutch population.
Number of subjects: 4900
Study: 38079634

Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Piecemeal endoscopic mucosal resection (EMR)
Number of subjects: 360
Study: 38081155

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 1822

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 1822

Group type: EXPERIMENTAL
Intervention: Abrocitinib (both dosages)
Number of subjects: 1822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1822
Study: 38081463

Group type: EXPERIMENTAL
Intervention: Minimally invasive SIJ fusion with triangular titanium implants (TTI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsurgical management (NSM)
Number of subjects: 0
Study: 38081585

Group type: EXPERIMENTAL
Intervention: Walnut diet (15% energy, 30-60 g/d; 2.6-5.2 g C18:3n-3/d)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control diet (abstention from walnuts)
Number of subjects: 115
Study: 38081671

Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) tools in healthcare
Number of subjects: 13
Study: 38081955

Group type: EXPERIMENTAL
Intervention: Daily oral pre-exposure prophylaxis (PrEP) for HIV prevention
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low adherence group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High adherence group
Number of subjects: 22
Study: 38082096

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 101
Study: 38082227

Group type: EXPERIMENTAL
Intervention: 1 µg/kg dexmedetomidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% normal saline (placebo)
Number of subjects: 60
Study: 38082231

Group type: EXPERIMENTAL
Intervention: FPSS (flavored PEG and sulfate solution)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PEG-SD (PEG and sports drink)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FPSS
Number of subjects: 60

Group type: COMPARATOR
Intervention: PEG-SD
Number of subjects: 60
Study: 38082248

Group type: EXPERIMENTAL
Intervention: Outdoor walk group (OWG) - met 2x/week for 10 weeks
Number of subjects: 190

Group type: COMPARATOR
Intervention: Weekly reminders (WR) group - received phone reminders 1x/week for 10 weeks
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Outdoor walk group (OWG)
Number of subjects: 190
Study: 38082255

Group type: EXPERIMENTAL
Intervention: Wearable-based gait assessments using three inertial sensors (LEGSys™, BioSensics LLC) during Timed Up and Go, 5 × sit-to-stand, and 2-min walk tests.
Number of subjects: 23
Study: 38082273

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 785
Study: 38082293

Group type: EXPERIMENTAL
Intervention: Palliative care practices implementation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Didactic Learning Sessions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Coaching visits by an expert
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Reflexive monitoring
Number of subjects: 10
Study: 38082337

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS) strategy involving PSA assessment, DRE, and periodic prostate biopsies every 6 months, multiparametric MRI every two years, and prostate biopsy at month 12 and then every two years.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS) strategy
Number of subjects: 200
Study: 38082350

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program
Number of subjects: 90

Group type: COMPARATOR
Intervention: Health promotion program
Number of subjects: 90
Study: 38082351

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI) program including education of ICU professionals, identification of patients at risk for agitation, formulation of a multidisciplinary person-centered care plan, and protocolized goal-directed light sedation using dexmedetomidine.
Number of subjects: 480

Group type: COMPARATOR
Intervention: Standard care with current agitation management protocol including physical restraints.
Number of subjects: 480
Study: 38082395

Group type: EXPERIMENTAL
Intervention: Integrated newborn care kit (iNCK) provided by Lady Health Workers (LHWs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local standard of care
Number of subjects: 0
Study: 38082431

Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavioral therapy (CBT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Wearable biosensor (Empatica)
Number of subjects: 40
Study: 38082486

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 660

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 660
Study: 38083399

Group type: EXPERIMENTAL
Intervention: Context-aware deep network (CADN) for coronary artery stenosis classification
Number of subjects: 0
Study: 38084398

Group type: EXPERIMENTAL
Intervention: Active tDCS (10 consecutive sessions, 20 minutes, 2 mA, two sessions a day over 5 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 34
Study: 38084590

Group type: EXPERIMENTAL
Intervention: Low-moderate hypothermia (20.1-24.0 °C)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Deep hypothermia (≤20.0 °C)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: High-moderate hypothermia (24.1-28.0 °C)
Number of subjects: 282
Study: 38084617

Group type: EXPERIMENTAL
Intervention: 10°C decaffeinated tea
Number of subjects: 30

Group type: COMPARATOR
Intervention: 50°C decaffeinated tea
Number of subjects: 30
Study: 38084725

Group type: EXPERIMENTAL
Intervention: 90 g of donor faeces once into the large intestine
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 90 g of donor faeces once into the small intestine
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 90 g of donor faeces twice into the small intestine
Number of subjects: 186
Study: 38084729

Group type: EXPERIMENTAL
Intervention: Endoscopist adenoma detection rate (ADR; low or high)
Number of subjects: 16551

Group type: COMPARATOR
Intervention: PCOL group
Number of subjects: 16551
Study: 38084760

Group type: EXPERIMENTAL
Intervention: Daratumumab combined with VRd induction and consolidation therapy and lenalidomide maintenance therapy (D-VRd group)
Number of subjects: 709

Group type: COMPARATOR
Intervention: VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Daratumumab combined with VRd
Number of subjects: 709

Group type: COMPARATOR
Intervention: VRd
Number of subjects: 709
Study: 38084840

Group type: EXPERIMENTAL
Intervention: ginisortamab
Number of subjects: 0
Study: 38084850

Group type: EXPERIMENTAL
Intervention: Virtual Scale Endoscope (VSE)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Visual Assessment (VA)
Number of subjects: 230
Study: 38084906

Group type: EXPERIMENTAL
Intervention: Daily samples for 10 days
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Daily rapid antigen tests (RATs)
Number of subjects: 101
Study: 38084933

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (active generator)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sacral neuromodulation (inactive generator)
Number of subjects: 46
Study: 38084941

Group type: EXPERIMENTAL
Intervention: hs-cTnI
Number of subjects: 8796

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 8796

Group type: EXPERIMENTAL
Intervention: hs-cTnI increase at 1 year
Number of subjects: 8796

Group type: EXPERIMENTAL
Intervention: hs-cTnI and hs-cTnT
Number of subjects: 8796
Study: 38085082

Group type: EXPERIMENTAL
Intervention: 4D cardiac CT-derived parameters
Number of subjects: 0
Study: 38085172

Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 0
Study: 38085184

Group type: EXPERIMENTAL
Intervention: Vaginal Estriol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microablative Fractional CO2 Laser
Number of subjects: 0
Study: 38085214

Group type: EXPERIMENTAL
Intervention: Pulsed-field ablation (PFA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 65
Study: 38085243

Group type: EXPERIMENTAL
Intervention: AcrySof IQ (SN6AT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: TECNIS (ZCT/ZMT)
Number of subjects: 58
Study: 38085296

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: DS107
Number of subjects: 46

Group type: COMPARATOR
Intervention: All clinical trials
Number of subjects: 46
Study: 38085312

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg orally twice per day from enrollment through delivery
Number of subjects: 831

Group type: COMPARATOR
Intervention: Placebo orally twice per day from enrollment through delivery
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Metformin plus insulin
Number of subjects: 831
Study: 38085428

Group type: EXPERIMENTAL
Intervention: Brief intervention (2 individual sessions and 2 phone calls)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined intervention (6 individual sessions and 3 group sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study: 38085470

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) administration of CoronaVac
Number of subjects: 173

Group type: COMPARATOR
Intervention: Intramuscular (IM) administration of CoronaVac
Number of subjects: 173
Study: 38085556

Group type: EXPERIMENTAL
Intervention: RP4 wearable patch
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: DW5 wearable patch
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: RW2 wearable patch
Number of subjects: 763
Study: 38085559

Group type: EXPERIMENTAL
Intervention: Serum glycated hemoglobin (HbA1c) levels
Number of subjects: 10773

Group type: EXPERIMENTAL
Intervention: Higher HbA1c levels
Number of subjects: 10773
Study: 38085621

Group type: EXPERIMENTAL
Intervention: Traditional-equipment RT (TRAD)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Minimal-equipment RT (MIN)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Minimal-equipment RT with BFR (MIN + BFR)
Number of subjects: 54
Study: 38085710

Group type: EXPERIMENTAL
Intervention: Digital individual Decision Aid (iDA) for cancer screening
Number of subjects: 0